Every 424B that Artelo Biosciences, Inc. (ARTL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ARTL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARTL filings page.
Artelo Biosciences, Inc. is offering up to $6,530,000 of common stock in an at-the-market program with H.C. Wainwright & Co., LLC as exclusive sales agent.
The sales agent will use commercially reasonable efforts to sell shares from time to time under an At the Market Offering Agreement dated May 26, 2026, and will receive a 3.0% commission. The offering is subject to Form S-3 resale limits under General Instruction I.B.6.
ARTL terminates its At-The-Market equity offering agreement effective May 18, 2026. The company had an ATM capacity of $6,500,000 and reports aggregate sales of 50,858 shares for gross proceeds of $451,526.95. The prospectus supplement ends the continuous offering under the ATM Prospectus.
The Sales Agreement with R.F. Lafferty & Co., Inc. was terminated by notice on May 11, 2026, effective May 18, 2026. The Common Stock trades on Nasdaq under the symbol ARTL; the last reported sales price on May 15, 2026 was $1.84.
Artelo Biosciences is registering up to 9,820,294 shares of Common Stock for resale. The shares consist of 81,000 issued shares, up to 3,107,407 shares issuable on Pre-Funded Warrants, up to 6,376,814 shares issuable on Common Warrants and up to 255,073 shares issuable on Placement Agent Warrants.
The Company is not selling any shares here and will not receive proceeds from resale by the Selling Stockholders; however, Artelo may receive up to $21,508,908.56 in gross proceeds if the Warrants and Placement Agent Warrants are exercised for cash. The prospectus discloses Beneficial Ownership Limitation provisions (4.99% or 9.99% election) and cashless-exercise conditions for certain Warrants.